AI assistant
EMYRIA LIMITED — Capital/Financing Update 2023
Apr 30, 2023
64844_rns_2023-04-30_fca30024-0940-4085-8d01-6cbb33d8c6a6.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Announcement Summary
Entity name
EMYRIA LIMITED
Announcement Type
New announcement
Date of this announcement
1/5/2023
The Proposed issue is:
==> picture [8 x 8] intentionally omitted <==
A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
| Maximum Number of | ||
|---|---|---|
| ASX +security code | +Security description | +securities to be issued |
| New class-code to be | Unquoted options exercisable at $0.30 each and expiring 2 | 16,666,666 |
| confirmed | years from date of issue. | |
| EMD | ORDINARY FULLY PAID | 16,666,666 |
Proposed +issue date
9/5/2023
Refer to next page for full details of the announcement
Proposed issue of securities
1 / 6
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 1 - Entity and announcement details
1.1 Name of +Entity
EMYRIA LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type
ACN
Registration Number 625085734
1.3 ASX issuer code
EMD
1.4 The announcement is
==> picture [8 x 8] intentionally omitted <==
New announcement
1.5 Date of this announcement
1/5/2023
1.6 The Proposed issue is:
==> picture [8 x 8] intentionally omitted <==
A placement or other type of issue
Proposed issue of securities
2 / 6
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? No
Part 7B - Issue details
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? Existing class
Details of +securities proposed to be issued
ASX +security code and description EMD : ORDINARY FULLY PAID Number of +securities proposed to be issued 16,666,666 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? Yes In what currency is the cash What is the issue price per consideration being paid? +security? AUD - Australian Dollar AUD 0.15000
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes
Proposed issue of securities
3 / 6
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Is the proposed security a 'New Will the proposed issue of this class' (+securities in a class that is +security include an offer of not yet quoted or recorded by ASX) attaching +securities? or an 'Existing class' (additional No securities in a class that is already quoted or recorded by ASX)? New class
Details of +securities proposed to be issued
ISIN Code (if Issuer is a foreign company and +securities are non CDIs)
Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed of the 'new' class of +securities on +securities are appropriate and ASX? equitable under listing rule 6.1? No No ASX +security code +Security description New class-code to be confirmed Unquoted options exercisable at $0.30 each and expiring 2 years from date of issue. +Security type Options Number of +securities proposed to be issued 16,666,666 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? No Please describe the consideration being provided for the +securities Participants in the placement announced to ASX on 1 May 2023 will receive 1 free option for every new placement share subscribed. Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities Will all the +securities issued in this class rank equally in all respects from their issue date? Yes
Proposed issue of securities
4 / 6
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
Options details
+Security currency Exercise price Expiry date AUD - Australian Dollar AUD 0.3000 9/5/2025
Details of the type of +security that will be issued if the option is exercised
EMD : ORDINARY FULLY PAID
Number of securities that will be issued if the option is exercised
1 option is exercisable into 1 ordinary fully paid share
Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement. https://emyria.com/for-investors/
Part 7C - Timetable
7C.1 Proposed +issue date
9/5/2023
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
==> picture [8 x 9] intentionally omitted <==
Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
16,666,666 options
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? Yes
7D.1c ( i ) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?
16,666,666 shares
7D.1c ( ii ) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate
A placement was seen to be an efficient, simple and cost effective method of raising funds for the Company.
Proposed issue of securities
5 / 6
Proposed issue of securities
==> picture [21 x 22] intentionally omitted <==
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No 7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No 7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue? Yes 7E.1a Who is the lead manager/broker? Joint Lead Managers to the Placement are Sixty Two Capital and Taylor Collison. 7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? 6% capital raising fee on funds raised by each respective Joint Lead Manager. 7E.2 Is the proposed issue to be underwritten? No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue N/A
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Support delivery of MDMA-assisted therapy, advance the Phase 3 clinical trial of EMD-RX5, support the US FDA registration preparations and to advance multiple preclinical screening programs. 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue Refer ASX announcement of 1 May 2023 for further information.
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Proposed issue of securities
6 / 6